Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Research & Development (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Research & Development for 11 consecutive years, with $4.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development rose 383.76% year-over-year to $4.2 million, compared with a TTM value of $4.9 million through Sep 2025, up 47.21%, and an annual FY2024 reading of $2.9 million, down 27.06% over the prior year.
  • Research & Development was $4.2 million for Q3 2025 at Kiora Pharmaceuticals, up from $1.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $4.2 million in Q3 2025 and bottomed at -$3.0 million in Q4 2024.
  • Average Research & Development over 5 years is $1.0 million, with a median of $1.1 million recorded in 2023.
  • The sharpest move saw Research & Development tumbled 368.11% in 2024, then surged 936.98% in 2025.
  • Year by year, Research & Development stood at $1.0 million in 2021, then crashed by 43.37% to $567227.0 in 2022, then soared by 95.98% to $1.1 million in 2023, then plummeted by 368.11% to -$3.0 million in 2024, then skyrocketed by 240.92% to $4.2 million in 2025.
  • Business Quant data shows Research & Development for KPRX at $4.2 million in Q3 2025, $1.7 million in Q2 2025, and $2.0 million in Q1 2025.